Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03836352 · ClinicalTrials.gov registry record · Phase 2
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
A Phase 2 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- Active
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 20
- Study locations
NCT03836352: Active Phase 2 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
NCT03836352 is a Phase 2 study of Non-Small Cell Lung Cancer and Ovarian Cancer that is active but no longer recruiting, run by ImmunoVaccine Technologies, Inc. (IMV Inc.). The registered enrollment target is 184 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03836352, a Phase 2 study of Non-Small Cell Lung Cancer and Ovarian Cancer, is active but no longer recruiting, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
Primary Outcome
Centrally evaluated using RECIST v1.1
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cyclophosphamide
- OTHER DPX-Survivac
Study Locations (20)
Ontario
- William Osler Health System - Brampton
- Juravinski Cancer Center - Hamilton
- Southlake Regional Health Center - Newmarket
- The Ottawa Hospital - Ottawa
- Sunnybrook Research Institute - Toronto
Florida
- Boca Raton Regional Hospital, Lynn Cancer Institute - Boca Raton
- Hematology Oncology Associates of the Treasure Coast - Port Saint Lucie
- Comprehensive Hematology and Oncology - St. Petersburg
New York
- NYU Winthrop Hospital - Mineola
- Montefiore Medical Center - The Bronx
Texas
- Mary Crowley Cancer Research Center - Dallas
- MD Anderson - Houston
Arizona
- The University of Arizona Cancer Center - Tucson
California
- Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center - Los Angeles
Georgia
- Winship Cancer Institute: The Emory Clinic - Atlanta
Kentucky
- James Brown Graham Cancer Center:University of Louisville Hospital - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 2 |
What the registry record for NCT03836352 still lists
NCT03836352 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (72% lower).
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03836352 names 20 study sites across 12 states, led by Ontario, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT03836352 about?
NCT03836352 is a clinical study titled "Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors". This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
What is the current status of trial NCT03836352?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2018-12-21. Estimated completion is 2023-12-31.
What conditions does trial NCT03836352 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Bladder Cancer, Hepatocellular Carcinoma, Microsatellite Instability High.
What interventions are being tested in trial NCT03836352?
The interventions under investigation include: Pembrolizumab (DRUG), Cyclophosphamide (DRUG), DPX-Survivac (OTHER).
Who is sponsoring clinical trial NCT03836352?
This trial is sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03836352 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03836352's enrollment target sits among peer trials
184 172nd of 454 higher than 282 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI